Jeevan Scientific Technology Successfully Concludes USFDA Inspection with Zero 483 Observations

Clinical research and biopharmaceutical services provider Jeevan Scientific Technology Limited (BSE: 538837) has formally disclosed the successful completion of a surveillance and study inspection by the United States Food and Drug Administration (USFDA).

The inspection was conducted at the company's Bioanalytical Facility situated at Manikonda in Hyderabad. The regulatory review commenced on July 20, 2026, and officially concluded on July 24, 2026.

The regulatory audit evaluated Bioavailability and Bioequivalence (BA/BE) studies conducted at the facility, along with a comprehensive review of operational systems, quality management procedures, and site infrastructure.

The USFDA regulatory team closed the inspection with No Observations (Zero Form 483s issued).

The successful inspection with zero observations reaffirms Jeevan Scientific Technology's compliance track record for its bioanalytical operations serving international pharmaceutical markets.

Shares of Jeevan Scientific Technology Ltd was last trading in BSE at Rs. 71.93 as compared to the previous close of Rs. 71.78. The total number of shares traded during the day was 24947 in over 200 trades.

The stock hit an intraday high of Rs. 76.00 and intraday low of 71.80. The net turnover during the day was Rs. 1838628.00.

Source : Equity Bulls

Keywords

JeevanScientificTechnology INE237B01018 HealthcareServices USFDA Inspection